A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2013 by Hospital Authority, Hong Kong
Sponsor:
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00578825
First received: December 20, 2007
Last updated: August 21, 2013
Last verified: August 2013

December 20, 2007
August 21, 2013
Not Provided
Not Provided
Development of severe SARS [ Time Frame: Any time during the acute illness ]
Same as current
Complete list of historical versions of study NCT00578825 on ClinicalTrials.gov Archive Site
  • Adverse events [ Time Frame: Throughout the illness period ]
  • SARS-CoV Viral load [ Time Frame: Throughout the illness period ]
  • Immunological profile [ Time Frame: Throughout the illness period ]
Same as current
Not Provided
Not Provided
 
A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Severe Acute Respiratory Syndrome
Drug: Lopinavir / Ritonavir plus Ribavirin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
340
Not Provided
Not Provided

Inclusion Criteria:

  • Male or female over the age of 18 with a diagnosis of SARS and with valid consent will be recruited.

Exclusion Criteria:

  • Subjects with medical conditions that makes the prescription of study medications unsafe are excluded.
Both
18 Years and older
Not Provided
Contact: Wai Cho Yu, Dr (852) 2990 3737 yuwc@ha.org.hk
China
 
NCT00578825
KW/FR/04-009, HARECCTR0500028, NTWC/CREC/349/05
Not Provided
Not Provided
Hospital Authority, Hong Kong
Not Provided
Principal Investigator: Wai Cho Yu, Dr Department of Medicine & Geriatrics, Princess Margaret Hospital
Hospital Authority, Hong Kong
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP